These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 37330326)

  • 1. Lenacapavir (Sunlenca®) for the treatment of HIV-1.
    Patel PC; Beasley HK; Hinton A; Wanjalla CN
    Trends Pharmacol Sci; 2023 Aug; 44(8):553-554. PubMed ID: 37330326
    [No Abstract]   [Full Text] [Related]  

  • 2. Lenacapavir (Sunlenca) for multidrug-resistant HIV.
    Med Lett Drugs Ther; 2023 May; 65(1675):68-70. PubMed ID: 37155250
    [No Abstract]   [Full Text] [Related]  

  • 3. Lenacapavir: First Approval.
    Paik J
    Drugs; 2022 Sep; 82(14):1499-1504. PubMed ID: 36272024
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lenacapavir: A novel injectable HIV-1 capsid inhibitor.
    Hitchcock AM; Kufel WD; Dwyer KAM; Sidman EF
    Int J Antimicrob Agents; 2024 Jan; 63(1):107009. PubMed ID: 37844807
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Highlights on the Development, Related Patents, and Prospects of Lenacapavir: The First-in-Class HIV-1 Capsid Inhibitor for the Treatment of Multi-Drug-Resistant HIV-1 Infection.
    Dzinamarira T; Almehmadi M; Alsaiari AA; Allahyani M; Aljuaid A; Alsharif A; Khan A; Kamal M; Rabaan AA; Alfaraj AH; AlShehail BM; Alotaibi N; AlShehail SM; Imran M
    Medicina (Kaunas); 2023 May; 59(6):. PubMed ID: 37374245
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lenacapavir: a first-in-class HIV-1 capsid inhibitor.
    Dvory-Sobol H; Shaik N; Callebaut C; Rhee MS
    Curr Opin HIV AIDS; 2022 Jan; 17(1):15-21. PubMed ID: 34871187
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lenacapavir: a twice-yearly treatment for adults with multidrug-resistant HIV infection and limited treatment options.
    Tuan J; Ogbuagu O
    Expert Rev Anti Infect Ther; 2023 Jun; 21(6):565-570. PubMed ID: 37067160
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antiviral Activity of Lenacapavir Against Human Immunodeficiency Virus Type 2 (HIV-2) Isolates and Drug-Resistant HIV-2 Mutants.
    Smith RA; Raugi DN; Nixon RS; Seydi M; Margot NA; Callebaut C; Gottlieb GS;
    J Infect Dis; 2024 May; 229(5):1290-1294. PubMed ID: 38060982
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lenacapavir and the novel HIV-1 capsid inhibitors: an emerging therapy in the management of multidrug-resistant HIV-1 virus.
    Lee NE; Sutherland RK
    Curr Opin Infect Dis; 2023 Feb; 36(1):15-19. PubMed ID: 36753704
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of the novel capsid inhibitor lenacapavir to treat multidrug-resistant HIV: week 52 results of a phase 2/3 trial.
    Ogbuagu O; Segal-Maurer S; Ratanasuwan W; Avihingsanon A; Brinson C; Workowski K; Antinori A; Yazdanpanah Y; Trottier B; Wang H; Margot N; Dvory-Sobol H; Rhee MS; Baeten JM; Molina JM;
    Lancet HIV; 2023 Aug; 10(8):e497-e505. PubMed ID: 37451297
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Capsid Inhibition with Lenacapavir in Multidrug-Resistant HIV-1 Infection.
    Segal-Maurer S; DeJesus E; Stellbrink HJ; Castagna A; Richmond GJ; Sinclair GI; Siripassorn K; Ruane PJ; Berhe M; Wang H; Margot NA; Dvory-Sobol H; Hyland RH; Brainard DM; Rhee MS; Baeten JM; Molina JM;
    N Engl J Med; 2022 May; 386(19):1793-1803. PubMed ID: 35544387
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lenacapavir: a new treatment of resistant HIV-1 infections.
    Mushtaq A; Kazi F
    Lancet Infect Dis; 2023 Mar; 23(3):286. PubMed ID: 36841248
    [No Abstract]   [Full Text] [Related]  

  • 13. Development and validation of an ultra-high performance liquid chromatography-tandem mass spectrometry method for quantifying lenacapavir plasma concentrations: Application to therapeutic monitoring.
    West RE; Oberly PJ; Riddler SA; Nolin TD; Devanathan AS
    J Chromatogr B Analyt Technol Biomed Life Sci; 2023 Nov; 1230():123905. PubMed ID: 37866010
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lenacapavir administered every 26 weeks or daily in combination with oral daily antiretroviral therapy for initial treatment of HIV: a randomised, open-label, active-controlled, phase 2 trial.
    Gupta SK; Berhe M; Crofoot G; Benson P; Ramgopal M; Sims J; McDonald C; Ruane P; Sanchez WE; Scribner A; Liu SY; VanderVeen LA; Dvory-Sobol H; Rhee MS; Baeten JM; Koenig E
    Lancet HIV; 2023 Jan; 10(1):e15-e23. PubMed ID: 36566079
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phenotypic resistance to lenacapavir and monotherapy efficacy in a proof-of-concept clinical study.
    Margot N; Vanderveen L; Naik V; Ram R; Parvangada PC; Martin R; Rhee M; Callebaut C
    J Antimicrob Chemother; 2022 Mar; 77(4):989-995. PubMed ID: 35028668
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lenacapavir for HIV-1 - Potential Promise of a Long-Acting Antiretroviral Drug.
    Marrazzo J
    N Engl J Med; 2022 May; 386(19):1848-1849. PubMed ID: 35544391
    [No Abstract]   [Full Text] [Related]  

  • 17. Evaluation of HIV-1 capsid genetic variability and lenacapavir (GS-6207) drug resistance-associated mutations according to viral clades among drug-naive individuals.
    Nka AD; Bouba Y; Teto G; Semengue ENJ; Takou DK; Ngueko AMK; Fabeni L; Carioti L; Armenia D; Pabo W; Dambaya B; Sosso SM; Colizzi V; Perno CF; Ceccherini-Silberstein F; Santoro MM; Fokam J; Ndjolo A
    J Antimicrob Chemother; 2022 Dec; 78(1):272-275. PubMed ID: 36411257
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lenacapavir: A Novel Long-Acting Capsid Inhibitor for HIV.
    Tailor MW; Chahine EB; Koren D; Sherman EM
    Ann Pharmacother; 2024 Feb; 58(2):185-195. PubMed ID: 37138515
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HIV-1 Group M Capsid Amino Acid Variability: Implications for Sequence Quality Control of Genotypic Resistance Testing.
    Tao K; Rhee SY; Tzou PL; Osman ZA; Pond SLK; Holmes SP; Shafer RW
    Viruses; 2023 Apr; 15(4):. PubMed ID: 37112972
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HIV-1 capsid inhibitors: a sword to destroy the virus.
    Zhang X; Xu S; Sun L; Ding D; Tao Y; Kang D; Liu X; Zhan P
    Future Med Chem; 2022 May; 14(9):605-607. PubMed ID: 35297282
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.